Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 251

The DOI matches its Crossref record.

Multiple myeloma treated with high dose intravenous melphalan

Selby, Peter J., McElwain, Timothy J., Nandi, Ann C., Perren, Timothy J., Powles, Raymond L., Tillyer, Colin R., Osborne, Richard J., Slevin, Maurice L., Malpas, James S. · 1987 · British Journal of Haematology

Abstract

High dose melphalan (HDM, 140 mg/m2 i.v.) has been evaluated in 58 patients under 63 years with multiple myeloma. Among previously untreated patients 11/41 (27%) entered a complete remission (CR: no measurable myeloma protein and a normal bone marrow) and 21 (51%) entered a partial remission (more than 50% reduction in myeloma protein and improvement in all other features). Median duration of remission is 19 months. Two patients who had responded to previous conventional treatment entered CR after HDM. Among 15 patients who had failed on previous chemotherapy the response rate was 66% including two CRs. However, in this group all patients have relapsed within 1 year. Profound myelosuppression, moderate nausea, vomiting, mucositis and diarrhoea with reversible alopecia occurred in all patients. There were 10 deaths within 2 months of treatment mainly due to sepsis and haemorrhage. In a subsequent study, high dose methyl prednisolone (1 g/m2 daily for 5 d) has been added to HDM. Response rates are similar with 6/22 (27%) CR, 13/22 (59%) PR and 2/22 NR but there was only one early death, reflecting improvements in medical management. The high CR rate is an encouraging feature of this approach which is now to be the basis of a prospective trial sponsored by the Medical Research Council in which HDM, with and without steroids, is compared to the best available conventional therapy (the MRC VI Myelomatosis trial).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2141.1987.00045.x-i1

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 251

Metadata

Authors
Selby, P. J., McElwain, T. J., Nandi, A. C., Perren, T. J., Powles, R. L., Tillyer, C. R., Osborne, R. J., Slevin, M. L., & Malpas, J. S.
Venue
British Journal of Haematology
Publisher
Wiley
Published
1987-05
Volume
66
Issue
1
Pages
55-62
ISSN
  • 0007-1048 (ISSN-L)
  • 1365-2141
OpenAlex
W1964073968
Cited by
251
References
0
FWCI
10.82
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Multiple myeloma treated with high dose intravenous melphalan. https://app.cochat.ai/papers/10.1111/j.1365-2141.1987.00045.x-i1
The paper
Selby, P. J., McElwain, T. J., Nandi, A. C., Perren, T. J., Powles, R. L., Tillyer, C. R., Osborne, R. J., Slevin, M. L., & Malpas, J. S. (1987). Multiple myeloma treated with high dose intravenous melphalan. British Journal of Haematology. https://doi.org/10.1111/j.1365-2141.1987.00045.x-i1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.